markets.businessinsider.com
Cure8 news brief
Why This Matters
This press release describes early-stage clinical development of two novel DR3-targeting antibodies being tested in Crohn’s disease and related immune-mediated conditions, which could represent new treatment approaches if trials show benefit and safety.
It’s relevant because it signals when key trial readouts are expected and highlights immunogenicity and dosing features the company is emphasizing.
Who Should Pay Attention
Patients with Crohn’s disease and other IBD interested in emerging biologic therapies; clinicians following new mechanisms (DR3 pathway, IL-23R bispecifics); researchers and investors tracking IBD drug development.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
Shattuck Labs reported initiation of a Phase 2b trial (RECEPTIVE-CD1) of SL-325 in moderately-to-severely active Crohn’s disease and plans for a Phase 2 trial in hidradenitis suppurativa; SL-846 preclinical/GLP toxicology data were presented and a Phase 1 for SL-846 is planned in 2027.
The company described trial designs (randomized, double-blind, placebo-controlled) and timelines for 12-week endoscopic response data in Crohn’s expected in H1 2028.
Keep In Mind
This is a company press release summarizing corporate and clinical-development milestones and preclinical findings; it is not a peer-reviewed study report. Trial results are not yet available; timelines and projected immunogenicity rates are company estimates. Data readouts are expected in 2027–2028 as described in the release.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmarkets.businessinsider.com
Authorsmarkets.businessinsider.com
Indexed viaGoogle News
Source typeWeb article
PublishedNov 5, 2026, 2:03 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect...
Shattuck Labs Incurs Higher Q2 Loss; To Advance SL-325 In Phase 2b For Crohn's Disease In Q3 '26
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...